Inogen, Inc (NASDAQ:INGN) shares reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $98.19 and last traded at $98.19, with a volume of 238,110 shares. The stock had previously closed at $96.50.

Several research analysts recently issued reports on the stock. BidaskClub lowered shares of Inogen from a “strong-buy” rating to a “buy” rating in a research report on Monday. Needham & Company LLC increased their price target on shares of Inogen from $96.00 to $108.00 and gave the stock a “strong-buy” rating in a research report on Friday, June 9th. Zacks Investment Research lowered shares of Inogen from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 11th. J P Morgan Chase & Co increased their price target on shares of Inogen to $102.00 and gave the stock an “overweight” rating in a research report on Monday, June 26th. Finally, Stifel Nicolaus increased their price target on shares of Inogen from $65.00 to $75.00 and gave the stock a “hold” rating in a research report on Wednesday, May 10th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $91.60.

The firm has a market capitalization of $2.02 billion, a PE ratio of 87.67 and a beta of 1.02. The stock has a 50-day moving average of $94.52 and a 200-day moving average of $80.91.

Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, May 9th. The medical technology company reported $0.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.15. The company had revenue of $52.50 million during the quarter, compared to the consensus estimate of $49.06 million. Inogen had a net margin of 9.32% and a return on equity of 11.67%. The firm’s revenue for the quarter was up 22.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.12 earnings per share. On average, equities research analysts expect that Inogen, Inc will post $1.09 EPS for the current fiscal year.

In other news, EVP Alison Bauerlein sold 6,666 shares of the stock in a transaction dated Wednesday, May 10th. The shares were sold at an average price of $83.24, for a total value of $554,877.84. Following the completion of the sale, the executive vice president now owns 25,758 shares in the company, valued at $2,144,095.92. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ray Benjamin M. Anderson sold 4,445 shares of the stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $81.05, for a total transaction of $360,267.25. Following the completion of the sale, the director now owns 4,445 shares of the company’s stock, valued at approximately $360,267.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 87,848 shares of company stock valued at $7,831,966. 5.31% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in INGN. FMR LLC increased its stake in shares of Inogen by 3.6% in the fourth quarter. FMR LLC now owns 207,600 shares of the medical technology company’s stock valued at $13,944,000 after buying an additional 7,300 shares in the last quarter. Guggenheim Capital LLC purchased a new stake in shares of Inogen during the fourth quarter valued at approximately $211,000. Norges Bank purchased a new stake in shares of Inogen during the fourth quarter valued at approximately $18,813,000. Teachers Advisors LLC increased its stake in shares of Inogen by 4.9% in the fourth quarter. Teachers Advisors LLC now owns 27,041 shares of the medical technology company’s stock valued at $1,816,000 after buying an additional 1,263 shares in the last quarter. Finally, Peregrine Capital Management LLC increased its stake in shares of Inogen by 4.9% in the first quarter. Peregrine Capital Management LLC now owns 397,789 shares of the medical technology company’s stock valued at $30,510,000 after buying an additional 18,543 shares in the last quarter.

WARNING: “Inogen, Inc (NASDAQ:INGN) Reaches New 12-Month High at $98.19” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/03/inogen-inc-nasdaqingn-reaches-new-12-month-high-at-98-19.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Receive News & Stock Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related stocks with our FREE daily email newsletter.